Clinical Trials Browser

Phase 1/2 × Interventional × Lenalidomide × Clear all

NCT03223610 2026-05-22

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Phase 1/2 Recruiting

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07600151 2026-05-20

CONQUISTADOR

Phase 1/2 Not yet recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04661007 2026-05-18

J-MIND

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05683171 2026-05-15

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Phase 1/2 Recruiting

Lymphoma

NCT04126200 2026-05-06

DREAMM 5

Phase 1/2 Active not recruiting

208 enrolled 5 charts

Multiple Myeloma

NCT04542824 2026-05-05

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04623541 2026-05-05

EPCORE™ CLL-1

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04663347 2026-05-05

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02343042 2026-05-04

STOMP

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05583617 2026-05-04

PLYCOM

Phase 1/2 Recruiting

Multiple Myeloma

NCT03523975 2026-04-22

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Mantle-Cell

NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Phase 1/2 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01054196 2026-04-08

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Phase 1/2 Active not recruiting

52 enrolled 15 charts

Multiple Myeloma

NCT01241734 2026-04-08

RICER

Phase 1/2 Completed

18 enrolled 15 charts

Lymphoma, Large B-Cell, Diffuse

NCT01297764 2026-03-23

QUAD

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT01615029 2026-03-16

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Phase 1/2 Completed

45 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1/2 Completed

55 enrolled 17 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

NCT05950165 2026-03-03

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Phase 1/2 Recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00378105 2026-02-24

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

Phase 1/2 Active not recruiting

68 enrolled 9 charts

Multiple Myeloma

NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Mantle-Cell

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms

NCT04669171 2026-01-30

SIDNEY

Phase 1/2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05222555 2026-01-16

MINDway

Phase 1/2 Active not recruiting

53 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT02302469 2025-11-28

RV-WM-0426

Phase 1/2 Completed

Waldenstrom Macroglobulinemia

NCT02937571 2025-11-20

High Dose Carfilzomib for Newly Diagnosed Myeloma

Phase 1/2 Completed

29 enrolled 10 charts

Multiple Myeloma

NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

113 enrolled 19 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

Phase 1/2 Enrolling by invitation

Multiple Myeloma

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04257448 2025-09-30

SEPION

Phase 1/2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT03015896 2025-09-29

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04446962 2025-09-25

LOC-R01

Phase 1/2 Active not recruiting

Lymphoma, Neurologic Manifestations, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms

NCT03011814 2025-09-18

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Phase 1/2 Active not recruiting

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05626322 2025-09-05

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1/2 Terminated

6 enrolled 17 charts

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07150091 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

Phase 1/2 Not yet recruiting

Infections, Epstein-Barr Virus Infections

NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Phase 1/2 Active not recruiting

17 enrolled 21 charts

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

NCT01995669 2025-06-24

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Phase 1/2 Completed

66 enrolled 13 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT06087653 2025-06-19

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Phase 1/2 Recruiting

Multiple Myeloma

NCT05265975 2025-06-09

SWATCH

Phase 1/2 Terminated

Lymphoma, Large B-Cell, Diffuse

NCT00112827 2025-06-06

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Phase 1/2 Completed

54 enrolled 13 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03544281 2025-03-18

DREAMM 6

Phase 1/2 Completed

153 enrolled 91 charts

Multiple Myeloma

NCT00670358 2025-01-10

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

Phase 1/2 Completed

138 enrolled 16 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05201248 2025-01-07

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Neoplasms, Lymphoma, B-Cell

NCT06762431 2025-01-07

VTB-CLL002

Phase 1/2 Enrolling by invitation

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04110301 2024-11-20

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Phase 1/2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT01755975 2024-11-07

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Phase 1/2 Completed

49 enrolled 15 charts

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Phase 1/2 Completed

20 enrolled 9 charts

GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor